Definitely possible. Biogen has no in-house drivers, their Alzheimer's drug has questions (Lilly's might be better and is ahead in development). Both are located in Boston and they probably could reduce overlap and workforces. Both are working on anti-lingo for MS. Definitely better leadership at Biogen then Vertex.
ABBVIE stretched itself to buy PCYC. JNJ also has rights to 50% of Imbruvica. They have deep pockets and should take out TGTX, Price will be much higher than 30. Plus, TGTX is essentially a future competitor to many companies with all its in-house combinations. GLTL
Rojo, this was all over the internet. Hope you picked up that it is years away. How expensive is it, is it ongoing inhalation. 3.5% is equivalent to what VRTX drugs provide NOW. What if VRTX triples and newer modalities go beyond 3.5%...Ireland was happy with 3.5% from this study., well that means they will pay for that now with Orkambi.
I expect Orkambi to be priced a little more than Kalydeco. Probably around $310K per year. Been a long since the 20s, and it has been a good ride. Expect big pharma to acquire. If it runs up with no acquirer, will take some off table.
Orchids, I am real, look me up. Long and strong!
Sentiment: Strong Buy
What more could we ask for. Monotherapy, dual therapy, and triple therapy with Imbruvica all demonstrating very good clinical outcomes with minimal side effects. Proprietary triple with Irak4 to start early stage trials this year. I don't believe anyone else has an Irak4 program. Great drugs to combine with larger pharma platforms. Totally undervalued and under appreciated by wall street currently. That will change.
Seek life Elsewhere. You have lost. VRTX will have two approved drugs soon, and continued expansion of their labels. At any moment a large pharma seeking such increasing revenue could make a bid. As a long (disclosure been long since the 20s) its comical to read about fake drop out rates (kuzykalex), the "biotech guru" piping non-existent phase 1 competitors (?how many years to a successful ph3 outcome) and the other dimwitted no names trying to post messages to scare investors and actually cause a drop in share price. Really? The reason some intelligent posters are here is to have a discussion of the science and the potential to help a patient population that has no good treatment modalities currently. They need even better drugs that what will be approved shortly. Not approving these upcoming drugs will limit research and innovation. At the end of the day, this is not just a stock, it is a hope to at least stabilize lung function and quality of life of people that did not volunteer to have such an illness. There are better stocks out there to short and ones that should not be supported by the social conscious.
You are no guru. There is no genie in Berkley, all shorts of VRTX burn now and in the future. Long and strong since the roaring 20s.
You always impress me with the obscure finds that you post. You are right to mention those names, they have been in this stock early and long! It is time for VRTX to start developing outside of CF, and to make bigger advances into CF with non-pharmacologic means as well.
Very superficial article, I just read it. They did not elaborate on the FDAs notes heading into the meeting. However, the best points were the comments from readers that argued against certain pharmacy benefit managers starting to complain about the cost potential of Orkambi. The readers diligently pointed out that Kalydeco isn't breaking the overall bank at 300K and that we are talking about 8500 patients. The pharmacy benefit managers rather put their profits into the CEO's pockets.
Absolutely Verity. As a Cardiologist, but not a physician, the role of the FDA in this case is to determine does the drug have efficacy (yes), is it safe (yes) then leave it up to physicians taking care of these patients to prescribe or not. These patients right now don't have any better option currently. I want to see them preserve their lung function and have less pulmonary exacerbations. Every visit to the hospital exposes any patient to virulent pathogens.
Agreed. With the HepC patients mostly international GILD revenue cannot be sustained. Acquiring VRTX CF franchise and pipeline would help sustain it over the long haul. If GILD pursues smaller targets, they will not be able to sustain current earnings IMHO.
He did not mention more competition. If anything having all combination compounds in-house will be a pricing and competitive advantage in the future. If upcoming data is as good as the smaller data sets, this will be a rocket within the next 12 months.